Logo image of EDIT

EDITAS MEDICINE INC (EDIT) Stock Price, Quote, News and Overview

NASDAQ:EDIT - Nasdaq - US28106W1036 - Common Stock - Currency: USD

1.945  -0.11 (-5.58%)

EDIT Quote, Performance and Key Statistics

EDITAS MEDICINE INC

NASDAQ:EDIT (2/21/2025, 1:06:07 PM)

1.945

-0.11 (-5.58%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High11.58
52 Week Low1.12
Market Cap160.56M
Shares82.55M
Float82.28M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)02-26 2025-02-26/amc
IPO02-03 2016-02-03


EDIT short term performance overview.The bars show the price performance of EDIT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40 -40 60

EDIT long term performance overview.The bars show the price performance of EDIT in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of EDIT is 1.945 USD. In the past month the price increased by 53.73%. In the past year, price decreased by -73.62%.

EDITAS MEDICINE INC / EDIT Daily stock chart

EDIT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.02 358.05B
AMGN AMGEN INC 15.1 160.69B
GILD GILEAD SCIENCES INC 23.96 137.62B
VRTX VERTEX PHARMACEUTICALS INC 1669.41 124.37B
REGN REGENERON PHARMACEUTICALS 15.32 76.45B
ARGX ARGENX SE - ADR N/A 39.37B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.09B
BNTX BIONTECH SE-ADR N/A 28.98B
ONC BEIGENE LTD-ADR N/A 27.09B
NTRA NATERA INC N/A 21.14B
BIIB BIOGEN INC 8.51 20.43B
SMMT SUMMIT THERAPEUTICS INC N/A 16.71B

About EDIT

Company Profile

EDIT logo image Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 265 full-time employees. The company went IPO on 2016-02-03. The firm is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The company is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).

Company Info

EDITAS MEDICINE INC

11 Hurley St

Cambridge MASSACHUSETTS 02141 US

CEO: James C. Mullen

Employees: 265

Company Website: https://www.editasmedicine.com/

Investor Relations: https://ir.editasmedicine.com

Phone: 16174019000

EDITAS MEDICINE INC / EDIT FAQ

What is the stock price of EDITAS MEDICINE INC today?

The current stock price of EDIT is 1.945 USD. The price decreased by -5.58% in the last trading session.


What is the ticker symbol for EDITAS MEDICINE INC stock?

The exchange symbol of EDITAS MEDICINE INC is EDIT and it is listed on the Nasdaq exchange.


On which exchange is EDIT stock listed?

EDIT stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for EDITAS MEDICINE INC stock?

22 analysts have analysed EDIT and the average price target is 4.53 USD. This implies a price increase of 133.07% is expected in the next year compared to the current price of 1.945. Check the EDITAS MEDICINE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is EDITAS MEDICINE INC worth?

EDITAS MEDICINE INC (EDIT) has a market capitalization of 160.56M USD. This makes EDIT a Micro Cap stock.


How many employees does EDITAS MEDICINE INC have?

EDITAS MEDICINE INC (EDIT) currently has 265 employees.


Is EDITAS MEDICINE INC (EDIT) expected to grow?

The Revenue of EDITAS MEDICINE INC (EDIT) is expected to grow by 14.24% in the next year. Check the estimates tab for more information on the EDIT EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy EDITAS MEDICINE INC (EDIT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does EDITAS MEDICINE INC (EDIT) stock pay dividends?

EDIT does not pay a dividend.


When does EDITAS MEDICINE INC (EDIT) report earnings?

EDITAS MEDICINE INC (EDIT) will report earnings on 2025-02-26, after the market close.


What is the Price/Earnings (PE) ratio of EDITAS MEDICINE INC (EDIT)?

EDITAS MEDICINE INC (EDIT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.56).


What is the Short Interest ratio of EDITAS MEDICINE INC (EDIT) stock?

The outstanding short interest for EDITAS MEDICINE INC (EDIT) is 20.77% of its float. Check the ownership tab for more information on the EDIT short interest.


EDIT Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to EDIT. When comparing the yearly performance of all stocks, EDIT is a bad performer in the overall market: 95.01% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

EDIT Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to EDIT. EDIT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

EDIT Financial Highlights

Over the last trailing twelve months EDIT reported a non-GAAP Earnings per Share(EPS) of -2.56. The EPS increased by 5.19% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -64.28%
ROE -119.89%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-36.36%
Sales Q2Q%-98.86%
EPS 1Y (TTM)5.19%
Revenue 1Y (TTM)150.84%

EDIT Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 70% to EDIT. The Buy consensus is the average rating of analysts ratings from 22 analysts.

For the next year, analysts expect an EPS growth of -33.3% and a revenue growth 14.24% for EDIT


Ownership
Inst Owners71.56%
Ins Owners0.28%
Short Float %20.77%
Short Ratio6.31
Analysts
Analysts70
Price Target4.53 (132.9%)
EPS Next Y-33.3%
Revenue Next Year14.24%